An FDA approval to market Lr-Et-EPA in the U.S. will, in short order, set in motion several concurrent events. -an AG for Vascepa will be promptly released by Amarin -generic companies will find it less profitable to continue with their infringing generic products, which are now up against a superior Lr-Et-EPA....and eventually they will discontinue their own infringing products -generic cos. will attempt to settle infringement lawsuits with Amarin - these settlements will add cash for Amarin to use for marketing their new superior drug
Market Data 
Markets 
AI
